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A meeting of regional experts was convened in Manila, Philippines, to develop a resource-stratified
chemotherapy-induced nausea and vomiting (CINV) management guideline. In patients treated
with highly emetogenic chemotherapy in general clinical settings, triple therapy with a serotonin
(5-hydroxytryptamine-3 [5-HT3]) antagonist (preferably palonosetron), dexamethasone, and aprepitant is
recommended for acute CINV prevention. In resource-restricted settings, triple therapy is still recom-
mended, although a 5-HT3 antagonist other than palonosetron may be used. In both general and resource-
restricted settings, dual therapy with dexamethasone (days 2 to 4) and aprepitant (days 2 to 3) is rec-
ommended to prevent delayed CINV. In patients treated with moderately emetogenic chemotherapy, dual
therapy with a 5-HT3 antagonist, preferably palonosetron, and dexamethasone is recommended for acute
CINV prevention in general settings; any 5-HT3 antagonist can be combined with dexamethasone in
resource-restricted environments. In general settings, for the prevention of delayed CINV associated with
moderately emetogenic chemotherapy, corticosteroid monotherapy on days 2 and 3 is recommended. If
aprepitant is used on day 1, it should be continued on days 2 and 3. Prevention of delayed CINV with
corticosteroids is preferred in resource-restricted settings. The expert panel also developed CINV
management guidelines for anthracycline plus cyclophosphamide combination schedules, multiday
cisplatin, and chemotherapy with low or minimal emetogenic potential, and its recommendations are
detailed in this review.Overall, these regional guidelinesprovidedefinitive guidance forCINVmanagement
in general and resource-restricted settings. These consensus recommendations are anticipated to
contribute to collaborative efforts to improve CINV management in Southeast Asia.
INTRODUCTION
Chemotherapy-induced nausea and vomiting
(CINV) is one of the most troublesome adverse
effects of cancer treatment, with a significant
negative impact on quality of life.1-3 Several new
treatments for CINVhavebeen introduced and are
now recommended in evidence-based antiemetic
guidelines developed by ASCO,4 the European
Society of Medical Oncology (ESMO) and Multi-
national Association of Supportive Care in Cancer
(MASCC),5 and the National Comprehensive
Cancer Network (NCCN).6 Although guideline-
recommended therapies significantly reduce the
risk of CINV, such regimens often are underused
in CINV prevention.7
Until recently, little has been documented about
the prevalence and management of CINV in the
Asia-Pacific region or the applicability of interna-
tional CINVmanagement guidelines to Asian pop-
ulations. International guidelines aremostly based
on studies conducted in white patients, but ethnic
differences and genetic polymorphisms may con-
tribute to CINV and affect the utility of antiemetic
treatment.3,8-11
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To optimize prevention and management of CINV
in Asian patients, regional guidelines should take
into account ethnic variations in CINV risk as well
as differences in health care systems, clinical
practice, and treatment availability and affordabil-
ity. A meeting of experts from Malaysia, the Phil-
ippines, and Singapore was convened in Manila,
Philippines, on November 24, 2014, to assess the
local applicability of international CINV manage-
ment guidelines and to develop regionally appro-
priate modifications. Principal considerations
were current clinical practice, treatment availabil-
ity and affordability, and specifics of local health
care systems. This article describes consensus-
based outcomes from the discussions at the Manila
meeting.
DISCUSSION
Burden of CINV in Asia
Several publications provide insight into CINV
characteristics and treatment in the Asia-Pacific
region.12-17 Observational studies inMalaysia, the
Philippines, and Singapore indicate that nausea
occurs more frequently than vomiting (Table 1).
However, the definitions for nausea and vomiting
vary among studies, which makes comparison of
the incidence difficult.
The following risk factors for CINV are the same in
Southeast Asia as in Europe:
·Type of chemotherapy administered. In a study
conducted among patients with head and
neck cancer in Singapore, single-day rather
than multiday cisplatin therapy was associ-
ated with a 1.5-fold increase in the risk of
nausea.12
·CINV experienced during previous chemo-
therapy.12,14,18 In a multinational, prospective,
observational study in patients who received
highly emetogenic chemotherapy (HEC) or mod-
erately emetogenic chemotherapy (MEC), pre-
vious CINV was a significant predictor of
subsequent vomiting and clinically significant
nausea and/or vomiting.18
Table 1. Incidence of Chemotherapy-Induced Nausea and Vomiting of Any Grade Reported in Malaysia, the Philippines,
and Singapore
First Author Country No. of Patients Chemotherapy Schedule Nausea (%) Vomiting (%)
Chan13 Malaysia 99 PC: 36.7% of patients
GEM: 16.7% of patients
DOX: 13.3% of patients
83.3 78.9
Williams15 Philippines 63 ALK, ANT, VIN, other* 73.0 52.4
Chan12 Singapore 235 IV CIS on day 1 of a 7-day (40 mg/m2) or
21-day (100 mg/m2) cycle
73.7 24.7
IV CIS 20 mg/m2/d and IV FU 1,000
mg/m2/d on days 1, 2, 3, and 4 of a
28-day cycle
48.9 28.9
Shih14 Singapore 91 IV DOX 60 mg/m2 1 CYC 600 mg/m2
every 14 or 21 days for up to five cycles
25.3† 68.1†
Yap16 Singapore 710 IV DOX 60mg/m2/d1 CYC 600mg/m2/d, or
IV DOX 50 mg/m2/d1 CYC 500 mg/m2/d
1 FU 500 mg/m2/d, or
IV EPI 75-100 mg/m2/d 1 CYC 500
mg/m2/d 1 FU 500 mg/m2/d, or
IV OXA 130 mg/m2/d 1 oral CAP
2,000 mg/m2/d, or
IV CIS 20-100 mg/m2/d 6 FU
1,000 mg/m2/d
55.0†
67.0‡
15.0†
22.0‡
Chan17 Singapore 156 CAP days 1-14 (median, 1,775 mg/m2/d)1
OXA day 1 (median, 104mg/m2) every 21
days
35.3†
46.8‡
6.4†
14.7‡
Abbreviations: ALK, alkylating agents (chlorambucil, cyclophosphamide, fluorouracil, thiotepa, busulfan); ANT, antimetabolites (fluorouracil,
capecitabine, mercaptopurine, methotrexate, gemcitabine, cytarabine, fludarabine); CAP, capecitabine; CIS, cisplatin; CYC, cyclophos-
phamide; DOX, doxorubicin; EPI, epirubicin; FU, fluorouracil; GEM, gemcitabine; IV, intravenous; OXA, oxaliplatin; PC, paclitaxel 1
carboplatin; VIN, vinca alkaloids (vinblastine, vincristine, vinorelbine).
*No indication given of proportion of patients who receive each chemotherapy.
†Acute nausea or vomiting.
‡Delayed nausea or vomiting.
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·Nonadherence to antiemetic therapy. In a large,
prospective study of patients with breast cancer
who received anthracycline-based chemother-
apy in Singapore, nonadherent patients were
less likely to achieve complete CINV control than
adherent patients (P 5 .048).19
·Anxiety and history of motion sickness. A study
of patients who received doxorubicin and cy-
clophosphamide for breast cancer found
that anxiety predicted development of acute
(P5 .004) and delayed nausea (P5 .024) and
that a history of motion sickness predicted delayed
vomiting (P5 .047).14
·Concomitant radiotherapy and poor perfor-
mance status. Among 235 patients treated
with cisplatin-based regimens for head and
neck cancer, concomitant radiotherapy was
associated with nausea (P 5 .022), and pa-
tients with an Eastern Cooperative Oncology
Group score > 1 were 2.4 times more likely to
experience vomiting (P 5 .046) than patients
with a score of 0.12
·Female sex and younger than 50 years of age.
The Pan Australasia Chemotherapy-Induced
Emesis (PrACTICE) study conducted in Asian
countries evaluated 648patients who received
HEC or MEC. Female versus male patients
were less likely to have a complete response
(no vomiting or use of rescue antiemetic
therapy) during chemotherapy cycles two and
three (P , .001). Patients younger than
50 years of age were more likely (P < .004) to
experience CINV in cycles two and three than
older patients.18
·Cancer-related fatigue. Poon et al20 evalu-
ated cancer-related fatigue scores in 473
patients with GI or breast cancers. Patients
with lower versus higher fatigue interference
scores were more likely to have a complete
response to antiemetics (odds ratio, 1.57;
P 5 .027).20
·Genetic polymorphisms in the ABCB1 trans-
porter gene. Particular haplotypes of the
ABCB1 gene are associated with an increased
risk of CINV.9-11 In Indonesia, the CTG haplo-
type is associated with an increased risk of
delayed CINV in patients who receive HEC.10
Similarly, the ABCB1 CG haplotype is associ-
ated with an increased risk of acute CINV in
Chinese patients during high-dose cytarabine
for acute myeloid leukemia,11 and the 3435C.T
polymorphism is a risk factor for acute CINV in
Japanese women who receive chemotherapy
for breast cancer.9
Low rates of alcohol use have been reported in
Asian patients with cancer,21,22 and a history of
low alcohol consumption has been linked with
chemotherapy-inducedemesis.23However,knowl-
edge is limited about the impact of alcohol use on
CINV in daily clinical practice.24
Antiemetic Therapy: Use of Guidelines and
Prescribing Patterns in Asia
The clinical management of CINV in the Asia-
Pacific has been investigated as part of the PrAC-
TICE study, a prospective, observational study
conducted in Australia, China, India, Singapore,
South Korea, and Taiwan.25 In PrACTICE, 84% of
physicians regularly used antiemetic guidelines,
with NCCN guidelines consulted by 65% of phy-
sicians, and MASCC/ESMO guidelines by 39%.26
Almost all physicians (97%) considered guide-
lines to be useful for CINV management.26
A high rate of serotonin (5-hydroxytryptamine-3
[5-HT3]) antagonist use (96% to 97%) is evident
in patients who receive HEC or MEC, but the pre-
scribing of other antiemetic therapies varies mark-
edly among countries.26 Among patients who have
received HEC, 95% in Australia also received
corticosteroids, but only 70% in China did; corre-
sponding rates of neurokinin-1 (NK1) antagonist
use were 91% and 0%, respectively. NK1 antag-
onist prescribing was probably affected by in-
ternational differences in drug availability and
reimbursement, whereas reasons for underuse
of corticosteroids are less clear.26
The PrACTICE study showed that corticosteroids
generally are underprescribed in Asian patients,
particularly in the delayed phase after HEC and
MEC.26 Some prescribers may not be aware of the
guideline recommendations for corticosteroids,
have concerns about the potential adverse effects
of administering corticosteroids for 3 to 4 days,
and/or lack confidence in these drugs’ antiemetic
efficacy.26 Underuse of corticosteroids may also
be partly related to cultural perceptions and
corticosteroid aversion in Asian patients.19,26,27
Dexamethasone is inexpensive, so to overcome
barriers to its use would improve CINV prophy-
laxis without significant additional treatment
costs.26 Asia-specific CINV management recom-
mendations may help to overcome barriers to
corticosteroid use and support rational use of
NK1 antagonists as they become more readily
available.
Consensus Development Process
The Manila panel discussed NCCN6 and MASCC/
ESMO5 recommendations and their applicability
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to Southeast Asia. These guidelines were selected
because they are the most widely used in the
region.26 For each recommendation, the panel
voted on the level of confidence and level of
consensus. Level of confidence (high, moderate,
or low)wasbasedon thepanel’s assessment of the
strength of the published evidence to support that
recommendation. Consensuswas defined as high
for seven votes, moderate for five or six votes, and
low for three or four votes. The panel also de-
veloped specific recommendations for resource-
limitedsettings so thatguidancecouldbeprovided
for oncologists who practice in areas with limited
access to newer and/or more costly antiemetics.
Resource-restricted settings were defined as hav-
ing the capacity to offer basic core antiemetic
therapy and any other antiemetic drugs that are
attainable with restricted financial means and
basic infrastructure. Higher-level resource set-
tings were defined as having the capacity to offer
important antiemetic therapy that would be diffi-
cult to attain and would not be standard therapy
in a resource-restricted setting but that may be
recommended in international guidelines regard-
less of resource constraints.
Since the Manila meeting in 2014, the MASCC
guidelines have been updated.28 Therefore, the
updated MASCC guidelines have been reviewed,
and an additional literature search of PubMedwas
conducted in July 2016 that used the search term
CINV to identify any other relevant evidence,with a
focus on studies conducted in the Asia-Pacific.
The consensus reached in 2014 remains essen-
tially unchanged except where indicated. Several
agents added to the 2016 MASCC/ESMO guide-
lines28 (rolapitant, netupitant plus palonosetron
combination)werenot available in theAsia-Pacific
at the time this article was submitted.
SUMMARY
Emetogenic Chemotherapies
NCCN6 andMASCC/ESMO5 guidelines both strat-
ified recommendations according to the emeto-
genic potential of chemotherapies. The Manila
panel agrees with the NCCN classification of HEC
or MEC intravenous agents,6 with some modifica-
tions (Table 2).
The panel recommends that cisplatin dosages
. 50mg/m2 be included in the HEC classification
(high confidence; high consensus), whereas
NCCN and MASCC/ESMO guidelines characterize
cisplatin as highly emetogenic, irrespective of
dosage.5,6,28 Although cisplatin generally is ad-
ministered at a dosage of . 50 mg/m2, lower
dosages sometimes are used (eg, in combination
with radiotherapy). Because evidence of a dose-
related effect of cisplatin on CINV exists,12 the
panel defines appropriate CINV management
recommendations for patients who receive
cisplatin , 50 mg/m2.
The panel also advocates a separate classification
for anthracycline plus cyclophosphamide (AC)
combination regimens (high confidence; high
consensus). Both the NCCN and 2016 MASCC/
ESMO guidelines classify AC combinations as
HEC.6,28 The earlier MASCC/ESMO recommen-
dations classified anthracyclines as MEC, ir-
respective of dosage, and cyclophosphamide
as HEC (at dosages > 1,500 mg/m2) or MEC
(, 1,500 mg/m2).28
Daunorubicin and idarubicin are listed as MECs,
regardless of dosage, in the NCCN guidelines,6
whereas doxorubicin and epirubicin are docu-
mentedasHECorMEC,whichdependsondosage.
NCCN also acknowledges that some anthracy-
clines (daunorubicin, doxorubicin, epirubicin)
may be highly emetogenic in some patients;
cyclophosphamide alone is categorized as
HEC at dosages . 1,500 mg/m2 or MEC at
doses < 1,500 mg/m2.6
The panel recommends that AC combinations be
labeled as a separate emetogenic category. Such
categorization permits specific antiemetic treat-
ment recommendations tobemade,whichclosely
reflect regional clinical practice (see the section
on antiemetic prophylaxis in patients who re-
ceive AC).
The panel concurs with the following NCCN cat-
egories for other emesis risk groups (low confi-
dence; high consensus): intravenous agents with
low or minimal emetogenicity and oral agents with
minimal to low or moderate to high emetic risk6
(Table 2). The emetogenic risk for oral antineo-
plastic agents is largely based on consensus and
data from registration trials in which patients often
receivedantiemeticprophylaxis.5Oncologistsshould
therefore be aware of the low level of confidence
in emetogenic classification for newer antineo-
plastics, particularly oral agents.
Antiemetic Prophylaxis
The Manila panel developed recommendations
for antiemetic use in the prevention and treatment
of acute and delayed CINV in patients who receive
various types of chemotherapy in general and
resource-restricted settings (Table 3). With re-
gard to resource stratification, treatment choice is
driven not only by drug acquisition cost but also
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by factors such as the overall cost-effectiveness of
antiemetic schedules, the potential for longer hos-
pital stays as a result of complications, patient loss
of income, patient willingness to pay, unexpected
hospital visits to control CINV between cycles, and
potentially increased costs to families if the patient
needs additional care.
Patients Who Receive HEC
Acute CINV. In most clinical settings, the panel
suggests triple therapy with a 5-HT3 antagonist
(preferably palonosetron), dexamethasone, and
aprepitant (high confidence; high consensus).
Support for this recommendation stems from data
from randomized, double-blind studies (including
one in Chinese patients) in which a 5-HT3 antag-
onist plus dexamethasone and aprepitant was
superior to a 5-HT3 antagonist plus dexametha-
sone in completely controlling CINV in patients
treated with HEC.29,30 In a trial in 411 Asian
patients, the complete response rate was signifi-
cantly greater with triple versus dual therapy dur-
ing the overall phase (0 to 120 hours after initiation
ofHEC;69.6% v57.0%;P5 .007) and thedelayed
phase (25 to 120 hours after initiation of HEC;
74.0% v59.4%;P, .001).30 In contrast to a study
in non-Asian patients, complete response rates
during the acute phase (0 to 24 hours after initi-
ation of HEC) were not significantly different for
triple versus dual therapy (79% for both regi-
mens). The relatively high acute phase complete
response rate observed in Asian patients treated
with dual therapy may have concealed the ad-
vantage of triple therapy observed in non-Asian
patients.29,30
Palonosetron is the recommended 5-HT3 antag-
onist. A meta-analysis of five randomized studies
in 2,057 patients showed that those treated with
palonosetron rather than dolasetron, granisetron,
or ondansetronhadasignificantly reduced relative
risk of acute nausea (–14%; P 5 .007), delayed
nausea (–18%; P, .001), acute vomiting (–24%;
P , .001), and delayed vomiting (–24%;
P, .001).31 In addition, palonosetron has a stron-
ger binding affinity at 5-HT3 receptors and a lon-
ger half-life (approximately 40 hours) than other
5-HT3 antagonists.
32 These findings explain the
clinical rationale for palonosetron to prevent acute
and delayed CINV.
The recommendeddosageof aprepitant inSouth-
east Asia is 125 mg orally 1 hour before chemo-
therapy.33 NCCN guidelines list either aprepitant
or fosaprepitant as appropriate NK1 antago-
nists for use in triple therapy schedules.6 The
2016 MASCC/ESMO guidelines recommend apre-
pitant, fosaprepitant, rolapitant, ornetupitant (avail-
able in combinationwith palonosetron),28 but the
latter two agents are not yet available in the Asia-
Pacific.
In resource-restricted settings, triple therapy is still
recommended, although it ismore expensive than
dual therapy.Data fromAsia, includingSingapore,
show that the additional acquisition cost of apre-
pitant is largely offset by reduced rescue medi-
cation use, hospitalization, and overall patient
management costs.34,35 However, if the acqui-
sition cost of aprepitant precludes its use as part
of a triple therapy regimen in resource-limited
Table 2. Manila Expert Panel Classification of Intravenous Agents With Moderate to High
Emetogenicity
High Risk* Special Case Moderate Risk†
Carmustine (. 250 mg/m2) Anthracycline 1
cyclophosphamide
combinations
Aldesleukin (. 12-15 million
IU/m2)
Cisplatin (. 50 mg/m2) Amifostine (. 300 mg/m2)
Cyclophosphamide
(. 1,500 mg/m2)
Arsenic trioxide
Dacarbazine Azacitadine
Doxorubicin (> 60 mg/m2) Bendamustine
Epirubicin (. 90 mg/m2) Busulfan
Ifosfamide (< 2 g/m2/dose) Carboplatin‡
Mechlorethamine Carmustine (< 250 mg/m2)
Streptozocin Cisplatin (< 50 mg/m2)
Clofarabine
Cyclophosphamide
(< 1,500 mg/m2)
Cytarabine (. 200 mg/m2)
Dactinomycin‡
Daunorubicin‡
Doxorubicin‡ (, 60 mg/m2)
Epirubicin‡ (< 90 mg/m2)
Idarubicin
Ifosfamide‡ (< 2 g/m2/dose)
Interferon alfa (< 10 million
IU/m2)
Irinotecan‡
Melphalan
Methotrexate‡ (> 250mg/m2)
Oxaliplatin
Temozolomide
Abbreviation: IU, International Unit.
*Emesis frequency . 90%.
†Emesis frequency 30% to 90%.
‡May be highly emetogenic in some patients.
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settings, olanzapine is an acceptable alterna-
tive,6 although further studies are needed on
the role of olanzapine to prevent CINV in patients
who receive HEC.
No specific cost-effectiveness data support the
useofpalonosetron in resource-restricted settings.
Thus, another 5-HT3 antagonist may be used as a
triple therapy constituent in patients who receive
HEC (high confidence; high consensus). If pa-
tients do not respond to one 5-HT3 antagonist,
another with a different metabolic pathway can
be tried because genetic polymorphisms in cy-
tochrome P450 (CYP) isoenzymes may lead to
interpatient differences in drug metabolism and
bioavailability.36 Table 4 lists the 5-HT3 antago-
nists typically used in Southeast Asia.5,36,37
Table 3. Consensus-Based Recommendations for the Use of Antiemetic Agents in Southeast Asia
CINV Type Setting Recommendation
Level of
Confidence
Level of
Consensus
Patients treated with HEC
Acute General Triple therapy with PAL 1 DEX 1 APR 125 mg High High
Resource limited Triple therapy with 5-HT3 1 DEX 1 APR 125 mg or
5-HT3 1 DEX 1 OLZ*
High High
Delayed General and resource limited DEX 8 mg on days 2-4 and APR 80 mg on days 2-3 High High
Patients treated with MEC
Acute General 5-HT3 antagonist (PAL preferred) 1 DEX 6 APR
125 mg†
Moderate High
Resource limited 5-HT3 antagonist 1 DEX or 5-HT3 1 DEX 1 OLZ* High High
Delayed General DEX 8 mg on days 2-3 6 APR 80 mg on days 2-3 (if
APR used on day 1)
High High
Resource limited DEX 8 mg on days 2-3 High High
Patients treated with AC
combinations
Acute General 5-HT3antagonist (PALpreferred)1DEX6APR125mg Moderate High
Resource limited 5-HT3 antagonist 1 DEX 6 APR 125 mg or 5-HT3
antagonist 1 DEX 1 OLZ
Moderate High
Delayed General DEX 8 mg on days 2-4 6 APR 80 mg on days 2-3 (if
APR used on day 1)
High High
Resource limited DEX 8 mg on days 2-4 6 APR 80 mg on days 2-3 (if
APR used on day 1) or DEX 1 OLZ or 5-HT3
antagonist (PAL preferred) 1 DEX on day 1
(corticosteroid sparing)
High High
Patients treatedwithmultiday
cisplatin
Acute General Triple therapy with PAL 1 DEX 1 APR 125 mg Moderate Moderate
Resource limited Triple therapy with 5-HT3 antagonist 1 DEX 6 APR
125 mg or 5-HT3 antagonist 1 DEX 1 OLZ
Moderate Moderate
Delayed General and resource limited DEX6 APR 80 mg on days 2-3 (if APR used on day 1) Moderate High
Chemotherapy with low
emetogenic risk
Acute General and resource limited 5-HT3 antagonist or DEX or DRA if antiemetics
considered appropriate
Low High
Delayed General and resource limited No routine prophylaxis High High
Chemotherapy with minimal
emetogenic risk
Acute or delayed General and resource limited No routine prophylaxis High High
Abbreviations: 5-HT3, 5-hydroxytryptamine-3; AC, anthracycline 1 cyclophosphamide; APR, aprepitant; CINV, chemotherapy-induced nausea and vomiting; DEX, dexa-
methasone; DRA, dopamine receptor antagonist; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; OLZ, olanzapine; PAL, palonosetron.
*Currently, limited data on OLZ efficacy in this setting.
†Patients should receive 5-HT3 antagonist and DEX in cycle 1, with APR added in subsequent cycles if dual therapy does not achieve CINV control.
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Delayed CINV. In all clinical settings in Southeast
Asia, the panel recommends the use of dual
therapy with dexamethasone (days 2 to 4)
and aprepitant (days 2 to 3) to prevent delayed
CINV (high confidence; high consensus), if re-
sources allow. Clinicians must not use aprepitant
on days 2 to 3 if it was not used on day 1 because
this is ineffective and wasteful. If aprepitant was
not used on day 1, the recommended regimen
for preventing delayed CINV is dexamethasone
monotherapy.
Typically, 5-HT3 antagonists are less effective in
preventingdelayed thanacuteCINV.A largemeta-
analysis revealed that the addition of a 5-HT3
antagonist (dolasetron, granisetron, or ondanse-
tron) to dexamethasone does not significantly
improve the antiemetic efficacy of dexamethasone
alone.38 Therefore, use of oral 5-HT3 antagonists
for the prevention of delayed CINV is not
recommended.
Although metoclopramide may be a low-cost
alternative to aprepitant for delayed CINV pre-
vention,39 equivalent efficacy has not been dem-
onstrated at doses approved for use in the Asia
Pacific, where amaximummetoclopramide dose
of 10 mg three times per day is recommended to
reduce the risk of neurologic and other dose-
related adverse drug reactions.40
Patients Who Receive MEC
Acute CINV. The Manila panel recommends dual
therapy with a 5-HT3 antagonist, preferably pal-
onosetron, anddexamethasone inpatients treated
withMEC inmost clinical settings inSoutheastAsia
(moderate confidence; high consensus). Palono-
setron is the preferred 5-HT3 antagonist because
data from multicenter, randomized, double-blind
trials have demonstrated superior antiemetic effi-
cacy relative to dolasetron41 and ondansetron42 in
patients who receive MEC. A meta-analysis of five
studies in 2,057 patients treated with HEC orMEC
revealed that palonosetron is significantly supe-
rior to dolasetron, granisetron, and ondansetron
in preventing both acute and delayed CINV.31
Limited evidence supports adding aprepitant to
combination therapy in patients who receive
MEC, and the panel recommends that oral apre-
pitant 125 mg33 only be added to dual therapy
(palonosetron 1 dexamethasone) in subsequent
cycles if CINV is not well controlled by dual therapy
in cycle 1; aprepitant shouldnot beused in the first
cycle (moderate confidence; high consensus).
MECs are not considered emetogenic enough to
warrant routine aprepitant use in patients who
receive these regimens. In an observational study
in Singapore in 156 patients treated with ca-
pecitabine plus oxaliplatin (which is moder-
ately emetogenic), 88% had no emesis during
dual therapy with a 5-HT3 antagonist and
dexamethasone.17
In resource-limited settings, any of the available
5-HT3 antagonists can be used in combination
with dexamethasone to prevent acute CINV in
patients treated with MEC, but aprepitant should
not because it lacks cost-effectiveness when
used with MEC (high confidence; high con-
sensus). Olanzapine is a low-cost alternative
to aprepitant if triple therapy is indicated,6 al-
though further studies are needed on the pre-
ventive efficacy of olanzapine in patients who
receive MEC.
Delayed CINV. In most clinical settings, the panel
recommends monotherapy with a corticosteroid
on days 2 and 3 to prevent delayed emesis; if
aprepitant is used on day 1, it should be continued
on days 2 and 3 (high confidence; high consen-
sus). Corticosteroids, which are inexpensive and
effective in preventing delayed CINV, are the pre-
ferred treatment in resource-limited settings (high
confidence; high consensus); a 5-HT3 antagonist
is a rational alternative for patients who cannot
tolerate corticosteroids.
Table 4. 5-HT3 Antagonists and Dosages Typically Used in Southeast Asia
HEC MEC
Agent IV Oral IV Oral
Granisetron 1 mg or 0.01 mg/kg 2 mg 1 mg or 0.01 mg/kg 2 mg
Ondansetron 8 mg or 0.15 mg/kg 24 mg 8 mg or 0.15 mg/kg 16 mg (or 8 mg twice daily)
Palonosetron 0.25 mg 0.5 mg 0.25 mg 0.5 mg
Ramosetron 300 mg* 100 mg 300 mg* 100 mg
Tropisetron 5 mg 5 mg 5 mg 5 mg
Abbreviations: 5-HT3, 5-hydroxytryptamine-3; HEC, highly emetogenic chemotherapy; IV, intravenous; MEC, moderately emetogenic chemotherapy.
*Maximum 600 mg/d.
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Patients Who Receive AC Combinations
Acute CINV. Patients who receive AC combination
therapy should be treated with a 5-HT3 antagonist
(preferably palonosetron) and dexamethasone;
oral aprepitant 125 mg can be added in centers
without limited resources (moderate confidence;
high consensus). In resource-limited centers, the
incremental benefit of aprepitant may not justify
the cost. An observational study of 91 patients
who received AC in Singapore found that most
patients tolerated AC chemotherapy moderately
well without vomiting.14 These patients received
CINV prophylaxis according to institutional guide-
lines, which recommended a 5-HT3 antagonist
plus corticosteroid during cycle 1 to prevent acute
CINV and a 5-HT3 antagonist plus corticosteroid
plus dopamine antagonist to prevent delayed
CINV. Patients who experienced CINV (acute
or delayed) during cycle 1 were given concom-
itant aprepitant during the next cycle, but only
nine patients required aprepitant in cycle 2.14
Thus, aprepitant should not be used routinely to
prevent acute CINV in patients treated with AC
in Asia (moderate confidence; high consensus),
but further studies are required. If triple therapy
is considered necessary, an acceptable low-cost
option is olanzapine with a 5-HT3 antagonist
and dexamethasone.6
Delayed CINV. Typically, corticosteroid dosages
used in Southeast Asia (Table 5) are lower than
those advocated in international guidelines for
CINV management.5,6 Thus, the panel recom-
mends therapywith dexamethasone8mg ondays
2 to 3 to prevent delayed emesis in patients treated
with AC in most settings. If resources allow, apre-
pitant 80 mg may be added, with the proviso that
aprepitant should be used in the delayed (days 2
to 3) antiemetic schedule only if used previously
on day 1 (moderate confidence; high consensus).
Alternative strategies in resource-limited settings
include an olanzapine-based regimen.6
Corticosteroid-sparing regimens may be another
option in resource-limited settings. In women
who receive AC regimens for breast cancer, a
corticosteroid-sparing regimen (single dose of
palonosetron then dexamethasone onday 1 only)
was no less effective in preventing delayed
CINV than continuation of dexamethasone for
3 days.43
Patients Who Receive Multiday Cisplatin
Multiday treatment with highly emetogenic sched-
ules presents unique challenges for CINV preven-
tion because patients may experience both acute
and delayed CINV, and the risk periods may over-
lap, depending on the chemotherapy schedules
used.6 Antiemetic therapy, therefore, should be
individualized and practical issues considered
(eg, administration in the inpatient v outpatient
setting, preferred route of administration, duration
of antiemetic action, tolerability profile, likely pa-
tient adherence to treatment).6 Recommenda-
tions from the Manila panel should be regarded
as general guidance only.
Acute CINV. In unrestricted resource settings in
Southeast Asia, patients treated with multiday
cisplatin should receive triple therapy with palo-
nosetron, dexamethasone, and aprepitant to pre-
vent acuteCINV.Data that support aprepitant use
come from a randomized, placebo-controlled,
crossover study in 69 patients with testicular
cancer who received a 5-day cisplatin-based
schedule.44 The addition of aprepitant to dexa-
methasone plus a 5-HT3 antagonist significantly
improved the complete response rate (42% v 13%
for triple v dual therapy, respectively; P, .001).44
However, aprepitant was scheduled over days 3
to 7 of therapy, which differs from the currently
approved 3-day dosing regimen of aprepitant.
Further studies are required to establish the role
and schedule of aprepitant in multiday cisplatin
chemotherapy.
In resource-limited environments, an inexpensive
5-HT3 antagonist should be used instead of pal-
onosetron, and aprepitant should be removed
from the triple therapy regimen (moderate confi-
dence; moderate consensus). This recommenda-
tion is substantiatedbyastudyconductedbyChan
et al12 in which 45 patients who received multi-
day (over 5 days) cisplatin received granisetron
and dexamethasone (without aprepitant) as anti-
emetic prophylaxis. Nausea and vomiting were
well controlled with 44.4% and 28.9% patients
who experienced significant nausea and vomit-
ing, respectively. Triple therapy with olanzapine, a
Table 5. Recommended Dexamethasone Dosages for CINV in Southeast Asia
Risk of CINV Type of CINV Recommended Dosage
High Acute 8-16 mg once (12 mg when used with
aprepitant)
Delayed 4-8 mg twice daily for 3-4 days (8 mg once
daily when used with aprepitant)
Moderate Acute 8 mg once
Delayed 8 mg once daily for 2-3 days
Low Acute 4-8 mg once
Abbreviation: CINV, chemotherapy-induced nausea and vomiting.
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5-HT3 antagonist, and dexamethasone is an ac-
ceptable and inexpensive alternative.
Delayed CINV. 5-HT3 antagonists generally are
less effective in the management of delayed
versus acute CINV.6,45 Thus, to prevent delayed
CINV in patients treated with multiday cisplatin-
containing schedules, the panel recommends
dexamethasone; aprepitant can be added where
resources permit (moderate confidence; high
consensus).
Chemotherapy With Low or Minimal Emetogenic
Risk
For patients who receive chemotherapy with low
emetogenic potential, physicians in the Asia-
Pacific should consider the omissionof antiemetics
to prevent acute CINV. Should antiemetics be
considered appropriate, theManila panel recom-
mends monotherapy with a 5-HT3 antagonist,
dexamethasone, or a dopamine-receptor antago-
nist (eg, metoclopramide) to prevent acute CINV
(lowconfidence;highconsensus); however, limited
evidence for this approach exists. Adding a 5-HT3
antagonist to single-agent therapy with dexameth-
asoneormetoclopramide isnotcost-effective in this
setting.46
No routine prophylaxis is needed to prevent
delayed CINV in patients who receive chemother-
apy with low emetogenic potential or to prevent
acute or delayed CINV in patients who receive
chemotherapy with minimal emetogenic poten-
tial (high confidence; high consensus). However,
these patients should be closely monitored; anti-
emetic therapy should beadministeredpromptly if
CINV occurs.
Anticipatory CINV
Effective control of CINV in the first cycle of che-
motherapy is essential because patients who ex-
perience CINV during cycle 1 are more likely to
have anxiety and anticipatory nausea before sub-
sequent cycles.47 Patients with anticipatory nau-
sea and vomiting may benefit from behavioral
therapies (high confidence; moderate consen-
sus). Benzodiazepines are the only agents that
have been shown to reduce the incidence of
anticipatory nausea and vomiting, but their effi-
cacy tends to decrease as chemotherapy con-
tinues (moderate confidence; low consensus).
Breakthrough/Refractory CINV
Despite the use of recommended prophylaxis,
CINV may still develop in some patients. Recom-
mendations for these patients are listed in Table 6.
Patients with breakthroughCINVmaybenefit from
switching antiemetic agents (eg, from one 5-HT3
antagonist to another).6,48 Evidence supports in-
terracial differences in genetic polymorphisms for
CYP enzymes,whichmay affect themetabolismof
various 5-HT3 antagonists, even between Asian
populations.36 Similarly, polymorphisms in the
genefor theABCB1efflux transportermayaffect the
rate at which various 5-HT3 antagonists cross the
blood-brain barrier and, therefore, their antiemetic
efficacy.9-11 This may explain some differences
between racial groups or between individuals
within the same racial group in the clinical effects
of certain 5-HT3 antagonists.
9-11,36,49 For switch-
ing between 5-HT3 antagonists, it is advisable to
choose an agent metabolized by a different CYP
enzymatic pathway and to use pharmacogenomic
information on the patient’s ABCB1 haplotype, if
available.
If a switch isnot effective or feasible, the additionof
an agent from a different class, such as a dopa-
mine antagonist,50 olanzapine,51 benzodiazepine,6
or phenothiazine, is recommended.6 Olanzapine
has been shown to be more effective than meto-
clopramide in this setting.51
In conclusion, effective CINV management is
best achieved by a multidisciplinary team, in-
cluding oncologists, pharmacists, and nurses.13,52
Through consultation and collaboration, better
prescribingchoices canbemade for patientswith
cancer53 that take into account the emetogenic
risk associated with various chemotherapy sched-
ules, specific patient characteristics, and pharma-
cologic and clinical profiles of antiemetic agents.
The current recommendations for CINV manage-
ment in Southeast Asia are unique because of
Table 6. Agents Considered by the Manila Panel as Suitable Treatment for Breakthrough
Chemotherapy-Induced Nausea and Vomiting
Agents Drug
Corticosteroids Dexamethasone
5-HT3 antagonists Dolasetron
Granisetron
Ondansetron
Ramosetron
Atypical antipsychotics Olanzapine
Short-acting benzodiazepines Lorazepam
Phenothiazines Prochlorperazine
Promethazine
Other Haloperidol
Metoclopramide
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their explicit regional focus and provide guidance
for resource-limitedcenters.Thecost-effectiveness
of various antiemetic regimens needs to be
evaluated to refine these recommendations
for resource-limited settings. Meanwhile, the
consensus outlined here is anticipated to con-
tribute to improvements in CINV management
in Asia.
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